EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.


:EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on 11q13 in proximity to CCND1, an established breast cancer oncogene, we also examined the amplification of CCND1 in the same tumor cohort. Amplification of EMSY and CCND1 were examined in 58 BRCA1-associated, 64 BRCA2-associated, and 242 familial non-BRCA1/BRCA2 breast cancers using fluorescent in situ hybridization (FISH). All tumors had a centralized pathology review and underwent molecular phenotyping by immunohistochemical profiling on tissue microarrays (TMAs). Tumors with amplification of EMSY and/or CCND1 were compared with non-amplified tumors for morphological appearance, molecular subtype, and overall survival. EMSY amplification was detected in 8% of BRCA1-associated, 0% of BRCA2-associated, and 9% of familial non-BRCA1/BRCA2 breast tumors (P = 0.036). CCND1 was amplified in 4% of BRCA1-associated, 13% of BRCA2-associated and 21% of non-BRCA1/BRCA2 breast tumors (P = 0.054). EMSY was amplified independently of CCND1 in 38% of cases. EMSY amplification was associated with increased tumor stage only; whereas CCND1 amplification was associated with high tumor grade, ER positivity, and inversely associated with the basal-like phenotype. There was a trend toward worse overall survival in ER-positive non-BRCA1/BRCA2 familial breast cancer patients whose tumors exhibited EMSY and CCND1 co-amplification. BRCA2-associated breast tumors are less likely than non-BRCA1/BRCA2 familial breast cancers to exhibit EMSY amplification. BRCA1-associated breast cancers are less likely than non-BRCA1/BRCA2 familial breast cancers to exhibit CCND1 amplification. EMSY amplification does occur independently of CCND1 amplification in a minority of familial breast cancers, supporting its role as a possible breast cancer oncogene.


Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL




Has Abstract


2011-06-01 00:00:00












  • The relationship of urinary and plasma androgens to steroid receptors and menopausal status in breast cancer patients and their influence on survival.

    abstract::The relationships between urinary 11-desoxy-17-oxo steroids (11-DOS), the ratio of 11-DOS to urinary 17-hydroxycorticosteroids (urinary discriminant ratio), plasma levels of the adrenal androgens dehydroepiandrosterone (DHA), DHA sulphate (DHAS), and 7 alpha-hydroxy DHA (7 alpha DHA), and tumour oestrogen receptor (ER...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Mason BH,Holdaway IM,Skinner SJ,Kay RG

    更新日期:1994-01-01 00:00:00

  • Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors.

    abstract::Clinical practice guidelines recommend yearly surveillance mammography for breast cancer survivors, yet many women do not receive this service. The objective of this study was to evaluate factors related to long-term surveillance mammography adherence among breast cancer survivors. We conducted a retrospective cohort ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Wirtz HS,Boudreau DM,Gralow JR,Barlow WE,Gray S,Bowles EJ,Buist DS

    更新日期:2014-02-01 00:00:00

  • Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells.

    abstract::Manganese superoxide dismutase (MnSOD) is known to play a role in cancer. MnSOD exerts a tumor suppressive effect in estrogen-dependent human breast cancer cells. In the present study we investigated the in vitro role of MnSOD in the growth of some aggressive and highly metastatic estrogen-independent breast cancer ce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Kattan Z,Minig V,Leroy P,Dauça M,Becuwe P

    更新日期:2008-03-01 00:00:00

  • Ethanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1.

    abstract::Alcohol consumption is a risk factor for breast cancer in humans. Experimental studies indicate that alcohol exposure promotes malignant progression of mammary tumors. However, the underlying cellular and molecular mechanisms remain unclear. Alcohol induces a pro-inflammatory response by modulating the expression of c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Wang S,Xu M,Li F,Wang X,Bower KA,Frank JA,Lu Y,Chen G,Zhang Z,Ke Z,Shi X,Luo J

    更新日期:2012-06-01 00:00:00

  • Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

    abstract::Medroxyprogesterone acetate (MPA) is well recognized to have beneficial effects for the treatment of advanced breast cancer which are comparable to those achieved with other forms of endocrine therapy. Using mammary tumors induced in the rat by dimethylbenz(a)anthracene (DMBA) as a model, we have studied the possibili...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Labrie F,Li S,Bélanger A,Côté J,Mérand Y,Lepage M

    更新日期:1993-01-01 00:00:00

  • Dietary intake from birth through adolescence in relation to risk of benign breast disease in young women.

    abstract:PURPOSE:Nutritional factors during different periods in life impact breast cancer risk. Because benign breast disease (BBD) is a well-established risk factor for breast cancer, we investigated childhood nutrition from birth through age 14 year and subsequent BBD. METHODS:A prospective cohort study of 9031 females, 9-1...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Berkey CS,Tamimi RM,Willett WC,Rosner B,Hickey M,Toriola AT,Lindsay Frazier A,Colditz GA

    更新日期:2019-09-01 00:00:00

  • Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).

    abstract::Bone lesions as a consequence of bone metastases in breast cancer patients can increase risk for skeletal-related events (SREs) (i.e., radiation to the bone, a pathological or osteoporotic fracture event, hypercalcemia, spinal cord compression, or surgery to the bone). The mortality risk for breast cancer patients wit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Yong M,Jensen AÖ,Jacobsen JB,Nørgaard M,Fryzek JP,Sørensen HT

    更新日期:2011-09-01 00:00:00

  • Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.

    abstract:PURPOSE:The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several brea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Kochi M,Iwamoto T,Niikura N,Bianchini G,Masuda S,Mizoo T,Nogami T,Shien T,Motoki T,Taira N,Tokuda Y,Doihara H,Matsuoka J,Fujiwara T

    更新日期:2018-01-01 00:00:00

  • Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

    abstract:PURPOSE:Ki-67 has been clinically validated for risk assessment in breast cancer, but the analytical validation and cutpoint-definition remain a challenge. Intraclass correlation coefficients (ICCs) are a statistical parameter for Ki-67 interobserver performance. However, the maximum degree of variance among pathologis...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Denkert C,Budczies J,Regan MM,Loibl S,Dell'Orto P,von Minckwitz G,Mastropasqua MG,Solbach C,Thürlimann B,Mehta K,Blohmer JU,Colleoni M,Müller V,Klauschen F,Ataseven B,Engels K,Kammler R,Pfitzner BM,Dietel M,Fasching

    更新日期:2019-08-01 00:00:00

  • Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors.

    abstract::Transforming growth factor-beta (TGFB) is a potent inhibitor of normal epithelial cell proliferation, and may be one of the regulatory factors that are perturbed during tumor development. While many tumor cell lines no longer respond to the inhibitory effects of TGFB due to a reduction or absence of the type II recept...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Barlow J,Yandell D,Weaver D,Casey T,Plaut K

    更新日期:2003-05-01 00:00:00

  • HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.

    abstract::The proto-oncogene, HER2, has prognostic and predictive relevance in invasive breast cancer (IBC). HER2 testing of primary IBC guides treatment selection and is assumed to reflect HER2 status of associated metastases, although HER2 discordance between IBC and metastasis has been reported. Systematic review and meta-an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析


    authors: Houssami N,Macaskill P,Balleine RL,Bilous M,Pegram MD

    更新日期:2011-10-01 00:00:00

  • Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).

    abstract::Current evidence suggests that the majority of DCIS lesions do not progress to invasive carcinoma, and overtreatment of DCIS is a significant problem. We previously reported an 8-gene signature that differentiated microdissected low-grade (LG) DCIS lesions with and without associated stromal invasion, based on differe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Geradts J,Groth J,Wu Y,Jin G

    更新日期:2016-06-01 00:00:00

  • Intra-operative ultrasound versus wire-guided localization in the surgical management of non-palpable breast cancers: systematic review and meta-analysis.

    abstract:INTRODUCTION:The current standard of treatment for non-palpable breast cancers is wire-guided localization (WGL). WGL has its drawbacks and alternatives such as radio-guided surgery (RGL) and intra-operative ultrasound (IOUS) have been developed. The clinical effectiveness of all forms of RGL has been assessed against ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审


    authors: Ahmed M,Douek M

    更新日期:2013-08-01 00:00:00

  • Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.

    abstract::The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Liu Y,Zhou R,Baumbusch LO,Tsavachidis S,Brewster AM,Do KA,Sahin A,Hortobagyi GN,Taube JH,Mani SA,Aarøe J,Wärnberg F,Børresen-Dale AL,Mills GB,Thompson PA,Bondy ML

    更新日期:2014-01-01 00:00:00

  • Outcomes of a weight loss intervention among rural breast cancer survivors.

    abstract::Obese breast cancer survivors have increased risk of recurrence and death compared to their normal weight counterparts. Rural women have significantly higher obesity rates, thus weight control intervention may be a key strategy for prevention of breast cancer recurrence in this population. This one-arm treatment study...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究


    authors: Befort CA,Klemp JR,Austin HL,Perri MG,Schmitz KH,Sullivan DK,Fabian CJ

    更新日期:2012-04-01 00:00:00

  • Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors.

    abstract::Treatment decisions in oncology are based on a balance between the efficacy of therapy and its side effects. Patients with metastases and patients with a limited prognosis are a particular challenge, since communication about the disease situation and the expected therapeutic benefit is difficult not only for patients...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Lux MP,Bayer CM,Loehberg CR,Fasching PA,Schrauder MG,Bani MR,Häberle L,Engel A,Heusinger K,Tänzer T,Radosavac D,Scharl A,Bauerfeind I,Gesslein J,Schulte H,Overbeck-Schulte B,Beckmann MW,Hein A

    更新日期:2013-06-01 00:00:00

  • Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

    abstract::The ability of the antiangiogenic agents TNP-470 and minocycline, singly or in combination, to potentiate the antitumor effects of several cytotoxic therapies was assessed in the murine EMT-6 mammary carcinoma as well as in two drug resistant sublines of that tumor designated EMT-6/CTX and EMT-6/CDDP. The antiangiogen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Teicher BA,Holden SA,Dupuis NP,Kakeji Y,Ikebe M,Emi Y,Goff D

    更新日期:1995-01-01 00:00:00

  • A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.

    abstract:PURPOSE:Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2-ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. R...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章


    authors: Watanabe J,Saito M,Horimoto Y,Nakamoto S

    更新日期:2020-05-01 00:00:00

  • Docetaxel-anthracycline combinations in metastatic breast cancer.

    abstract::The taxanes and anthracyclines have emerged as the most active agents for treating women with advanced breast cancer. As such, investigation of the two drug classes in combination regimens has been eagerly pursued. The rationale for combining docetaxel with an anthracycline includes high clinical activity of each indi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审


    authors: Nabholtz JM

    更新日期:2003-01-01 00:00:00

  • Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.

    abstract::The transcriptome of breast cancers have been extensively screened with microarrays and large sets of genes associated with clinical features have been established. The aim of this study was to validate original gene sets on a large cohort of raw breast cancer microarray data with known clinical follow-up. We recovere...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析


    authors: Györffy B,Schäfer R

    更新日期:2009-12-01 00:00:00

  • Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.

    abstract::The gene for Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (Pnck), a novel calmodulin kinase, is expressed in roughly one-third of human breast tumors, but not in adjoining normal tissues. Pnck alters EGFR stability and function, prompting this study to determine if Pnck expression has implications for HER-2...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Deb TB,Zuo AH,Barndt RJ,Sengupta S,Jankovic R,Johnson MD

    更新日期:2015-04-01 00:00:00

  • Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.

    abstract::E6-associated protein (E6-AP) is a dual function protein. It acts as an E3 ubiquitin-protein ligase enzyme and coactivator of steroid hormone receptors such as estrogen (ERα) and progesterone (PR) receptors. It promotes the degradation of ERα and PR through the ubiquitin-proteasome pathway. Furthermore, it has been sh...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Ramamoorthy S,Tufail R,Hokayem JE,Jorda M,Zhao W,Reis Z,Nawaz Z

    更新日期:2012-02-01 00:00:00

  • Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.

    abstract::The purpose of this study is to compare immunohistochemistry (IHC) and cytosol-based assays for determination of estrogen receptor (ER) and prediction of response to adjuvant tamoxifen treatment in postmenopausal women with early-stage invasive breast cancer. The Stockholm Breast Cancer Study Group conducted a randomi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验


    authors: Khoshnoud MR,Löfdahl B,Fohlin H,Fornander T,Stål O,Skoog L,Bergh J,Nordenskjöld B

    更新日期:2011-04-01 00:00:00

  • Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial.

    abstract::A potential advantage of primary over adjuvant chemotherapy in breast cancer survival had been proposed on theoretical grounds. In 1994, early results of the S6-trial comparing primary chemotherapy vs. adjuvant chemotherapy for operable breast cancer in 390 premenopausal patients had shown significant improvement in s...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Broët P,Scholl SM,de la Rochefordière A,Fourquet A,Moreau T,De Rycke Y,Asselain B,Pouillart P

    更新日期:1999-11-01 00:00:00

  • Adjuvant systemic therapy: state of the art, 1989.

    abstract::After more than 100 reported randomized trials of systemic adjuvant therapy in breast cancer, it is clear that this therapy will prolong the time to recurrence and the survival time significantly, at least in some patient subsets. But there is less than complete agreement as to which subsets, which therapies, how much...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验,评审


    authors: Henderson IC

    更新日期:1989-10-01 00:00:00

  • Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models.

    abstract::Considerable effort has been placed into the identification of new antineoplastic agents to treat breast cancer and other malignant diseases. The basic approaches, in terms of model selection, endpoints, and data analysis, have changed in the previous few decades. This article deals with many of the issues associated ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审


    authors: Clarke R

    更新日期:1997-11-01 00:00:00

  • Association study of susceptibility loci with specific breast cancer subtypes in Chinese women.

    abstract::To determine whether recent genome-wide association studies that reported 45 susceptibility loci in European women are also risk factors for breast cancer in Chinese women. We selected and genotyped 40 single nucleotide polymorphisms (SNPs) using the Sequenom iPlex platform in a female Chinese cohort of 2,901 breast c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Zhang B,Li Y,Li L,Chen M,Zhang C,Zuo XB,Zhou FS,Liang B,Zhu J,Li P,Huang ZL,Xuan H,Li W,Chen ZD

    更新日期:2014-08-01 00:00:00

  • Generation of CD8+ cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A-pulsed dendritic cells.

    abstract::Mammaglobin-A is exclusively expressed by breast cancer cells. Thus, mammaglobin-A-specific T cell immune responses may be useful for the design of new breast cancer-specific immunotherapies. We show herein that CD8+ T cells generated against recombinant mammaglobin-A-pulsed dendritic cells display a marked cytotoxic ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Manna PP,Jaramillo A,Majumder K,Campbell LG,Fleming TP,Dietz JR,Dipersio JF,Mohanakumar T

    更新日期:2003-05-01 00:00:00

  • Establishment and characterization of two new cell lines derived from human metastatic breast carcinomas.

    abstract::Two human cancer cell lines (MA 2 and MA 3) were established from pleural effusions of infiltrating ductal carcinomas of the breast. The lines were maintained in continuous monolayer culture with doubling times of 70 (MA 2) and 78 (MA 3) hr for more than two years and possessed extensively rearranged abnormal karyo-ty...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Zoli W,Roncuzzi L,Zini N,Lenzi L,Gruppioni R,Barzanti F,Sensi A,Amadori D,Gasperi-Campani A

    更新日期:1997-04-01 00:00:00

  • Trajectories of quality of life following breast cancer diagnosis.

    abstract:PURPOSE:Although quality of life (QoL) improves over time for most breast cancer survivors (BCS), BCS may show different patterns of QoL. This study sought to identify distinct QoL trajectories among BCS and to examine characteristics associated with trajectory group membership. METHODS:BCS (N = 653) completed baselin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章


    authors: Goyal NG,Levine BJ,Van Zee KJ,Naftalis E,Avis NE

    更新日期:2018-05-01 00:00:00